Related references
Note: Only part of the references are listed.Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Robert J. Motzer et al.
CANCER (2020)
The Immunotherapy Revolution in Kidney Cancer Treatment Scientific Rationale and First-Generation Results
Elshad Hasanov et al.
CANCER JOURNAL (2020)
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing et al.
LANCET ONCOLOGY (2019)
Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?
Sumanta Pal et al.
LANCET ONCOLOGY (2019)
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Michael B. Atkins et al.
CANCER TREATMENT REVIEWS (2018)
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
Nizar M. Tannir et al.
ONCOLOGIST (2018)
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing et al.
CANCER CELL (2018)
A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
Simon Chowdhury et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production
Jeffrey A. Sosman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Role of IL-10 for induction of anemia during inflammation
H Tilg et al.
JOURNAL OF IMMUNOLOGY (2002)
Share Paper
